Taxotere
Advance Directives, Advance Directives, Metastatic Hormone-Refractory Prostate Cancer + 13 more
Treatment
20 FDA approvals
20 Active Studies for Taxotere
Treatment for
Advance Directives
What is Taxotere
Docetaxel
The Generic name of this drug
Treatment Summary
Docetaxel is an anti-cancer drug used to treat breast, ovarian, and non-small cell lung cancer. The medication works by binding to a protein found in cells called tubulin, which stops the growth of cancer cells.
Taxotere
is the brand name
Taxotere Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Taxotere
Docetaxel
2008
97
Approved as Treatment by the FDA
Docetaxel, also known as Taxotere, is approved by the FDA for 20 uses such as locally advanced untreated non small cell lung cancer and Carcinoma, Non-Small-Cell Lung .
locally advanced untreated non small cell lung cancer
Used to treat locally advanced untreated non small cell lung cancer in combination with Cisplatin
Carcinoma, Non-Small-Cell Lung
Used to treat metastatic untreated non small cell lung cancer in combination with Cisplatin
Neoplasm Metastasis
Metastatic Hormone-Refractory Prostate Cancer
Used to treat refractory, metastatic hormone-refractory Prostate cancer in combination with Prednisone
Node Positive Breast Cancer
Used to treat Node Positive Breast Cancer in combination with Cyclophosphamide
Advance Directives
Used to treat advanced untreated gastric adenocarcinoma in combination with Cisplatin
metastatic untreated non small cell lung cancer
Used to treat metastatic untreated non small cell lung cancer in combination with Cisplatin
Non-Small Cell Lung Carcinoma
Metastatic Breast Cancer
Advance Directives
Ovarian Cancer Metastatic
refractory, metastatic Non small cell lung cancer
refractory, metastatic hormone-refractory Prostate cancer
Used to treat refractory, metastatic hormone-refractory Prostate cancer in combination with Prednisone
Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Metastatic Breast Cancer
Squamous Cell Carcinoma of Head and Neck
BRCA1 gene
Malignant Neoplasms
Used to treat Node Positive Breast Cancer in combination with Cyclophosphamide
Advance Directives
Used to treat locally advanced untreated non small cell lung cancer in combination with Cisplatin
Advance Directives
Used to treat locally advanced Squamous cell carcinoma of head and neck in combination with Cisplatin
Effectiveness
How Taxotere Affects Patients
Docetaxel is a drug used to treat cancer. It helps create and stabilize microtubules, which are necessary for many cell functions. Docetaxel also changes the way microtubules are organized, which can prevent cancer cells from dividing and growing.
How Taxotere works in the body
Docetaxel stops cancer cells from reproducing by blocking the growth of their microtubules. This is done by locking the "building blocks" of microtubules (tubulin) in place, preventing them from moving around. This interferes with cell function, as this movement of microtubules is important for transporting chromosomes during mitosis (cell division). Additionally, docetaxel works by binding to a protein called Bcl-2, which stops cells from undergoing programmed cell death (apoptosis). By binding to this protein, docetaxel prevents it from working and allows the cell to die.
When to interrupt dosage
The advised dosage of Taxotere is contingent upon the determined condition, for example, Esophageal Cancer, Neoplasm Metastasis and Non-Small Cell Lung Carcinoma. The measure of dosage deviates, in accordance with the approach of administration (e.g. Intravenous or Injection, solution, concentrate - Intravenous) presented in the following table.
Condition
Dosage
Administration
Metastatic Hormone-Refractory Prostate Cancer
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, , Kit, Injection, solution - Intravenous, Injection, solution, Injection - Intravenous, Injection, Solution - Intravenous, Solution, Kit; Solution, Kit; Solution - Intravenous
Malignant Neoplasms
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, , Kit, Injection, solution - Intravenous, Injection, solution, Injection - Intravenous, Injection, Solution - Intravenous, Solution, Kit; Solution, Kit; Solution - Intravenous
Small Cell Lung Cancer
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, , Kit, Injection, solution - Intravenous, Injection, solution, Injection - Intravenous, Injection, Solution - Intravenous, Solution, Kit; Solution, Kit; Solution - Intravenous
Urinary Bladder Neoplasms
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, , Kit, Injection, solution - Intravenous, Injection, solution, Injection - Intravenous, Injection, Solution - Intravenous, Solution, Kit; Solution, Kit; Solution - Intravenous
Soft Tissue Sarcoma
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, , Kit, Injection, solution - Intravenous, Injection, solution, Injection - Intravenous, Injection, Solution - Intravenous, Solution, Kit; Solution, Kit; Solution - Intravenous
Neoplasm Metastasis
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, , Kit, Injection, solution - Intravenous, Injection, solution, Injection - Intravenous, Injection, Solution - Intravenous, Solution, Kit; Solution, Kit; Solution - Intravenous
Squamous Cell Carcinoma of Head and Neck
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, , Kit, Injection, solution - Intravenous, Injection, solution, Injection - Intravenous, Injection, Solution - Intravenous, Solution, Kit; Solution, Kit; Solution - Intravenous
Advance Directives
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, , Kit, Injection, solution - Intravenous, Injection, solution, Injection - Intravenous, Injection, Solution - Intravenous, Solution, Kit; Solution, Kit; Solution - Intravenous
Advance Directives
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, , Kit, Injection, solution - Intravenous, Injection, solution, Injection - Intravenous, Injection, Solution - Intravenous, Solution, Kit; Solution, Kit; Solution - Intravenous
Advance Directives
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, , Kit, Injection, solution - Intravenous, Injection, solution, Injection - Intravenous, Injection, Solution - Intravenous, Solution, Kit; Solution, Kit; Solution - Intravenous
Non-Small Cell Lung Carcinoma
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, , Kit, Injection, solution - Intravenous, Injection, solution, Injection - Intravenous, Injection, Solution - Intravenous, Solution, Kit; Solution, Kit; Solution - Intravenous
Sarcoma
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, , Kit, Injection, solution - Intravenous, Injection, solution, Injection - Intravenous, Injection, Solution - Intravenous, Solution, Kit; Solution, Kit; Solution - Intravenous
BRCA1 gene
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, , Kit, Injection, solution - Intravenous, Injection, solution, Injection - Intravenous, Injection, Solution - Intravenous, Solution, Kit; Solution, Kit; Solution - Intravenous
Advance Directives
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, , Kit, Injection, solution - Intravenous, Injection, solution, Injection - Intravenous, Injection, Solution - Intravenous, Solution, Kit; Solution, Kit; Solution - Intravenous
Metastatic Breast Cancer
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, , Kit, Injection, solution - Intravenous, Injection, solution, Injection - Intravenous, Injection, Solution - Intravenous, Solution, Kit; Solution, Kit; Solution - Intravenous
Carcinoma, Non-Small-Cell Lung
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, , Kit, Injection, solution - Intravenous, Injection, solution, Injection - Intravenous, Injection, Solution - Intravenous, Solution, Kit; Solution, Kit; Solution - Intravenous
Warnings
Taxotere has one contraindication and should not be used when encountering the conditions contained in the following table.
Taxotere Contraindications
Condition
Risk Level
Notes
neutrophil count <1500 cells/mm3
Do Not Combine
There are 20 known major drug interactions with Taxotere.
Common Taxotere Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Docetaxel is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Docetaxel is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Docetaxel.
Abetimus
Major
The risk or severity of adverse effects can be increased when Docetaxel is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Docetaxel is combined with Acteoside.
Taxotere Toxicity & Overdose Risk
The most toxic dose of this drug in rats is greater than 2000mg/kg. An overdose could lead to problems with the bone marrow, peripheral nerve damage, and irritation of the mucous membranes. Two people who overdosed on this drug experienced severe low white blood cell counts, fatigue, skin reactions, and tingling. They both recovered without any major problems.
Taxotere Novel Uses: Which Conditions Have a Clinical Trial Featuring Taxotere?
378 active trials are being conducted to assess the potential of Taxotere to combat metastatic untreated non small cell lung cancer, Sarcoma and Advance Directives.
Condition
Clinical Trials
Trial Phases
Metastatic Hormone-Refractory Prostate Cancer
79 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 4, Phase 3, Early Phase 1
Metastatic Breast Cancer
1 Actively Recruiting
Phase 1, Phase 2
BRCA1 gene
12 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Early Phase 1, Phase 3
Non-Small Cell Lung Carcinoma
714 Actively Recruiting
Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1
Advance Directives
0 Actively Recruiting
Small Cell Lung Cancer
50 Actively Recruiting
Phase 2, Phase 3, Phase 1, Not Applicable, Early Phase 1
Advance Directives
0 Actively Recruiting
Carcinoma, Non-Small-Cell Lung
0 Actively Recruiting
Neoplasm Metastasis
1 Actively Recruiting
Phase 2
Soft Tissue Sarcoma
51 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 4, Early Phase 1, Phase 3
Advance Directives
0 Actively Recruiting
Squamous Cell Carcinoma of Head and Neck
6 Actively Recruiting
Phase 1, Phase 2, Phase 3
Sarcoma
1 Actively Recruiting
Phase 2
Advance Directives
0 Actively Recruiting
Malignant Neoplasms
4 Actively Recruiting
Not Applicable, Phase 2
Urinary Bladder Neoplasms
0 Actively Recruiting
Taxotere Reviews: What are patients saying about Taxotere?
4.7
Patient Review
8/8/2016
Taxotere for Breast Cancer
3.7
Patient Review
4/13/2015
Taxotere for Cancer of Prostate that has Spread to Other Part of Body
3.3
Patient Review
6/29/2011
Taxotere for Cancer of Prostate that has Spread to Other Part of Body
3.3
Patient Review
3/3/2010
Taxotere for Breast Cancer
3.3
Patient Review
1/31/2013
Taxotere for Cancer Involving the Head or Neck
2.7
Patient Review
8/18/2011
Taxotere for Non-Small Cell Lung Cancer
2.7
Patient Review
3/5/2010
Taxotere for Non-Small Cell Lung Cancer
2.3
Patient Review
7/20/2011
Taxotere for Breast Cancer that has Spread to Another Part of the Body
2
Patient Review
9/11/2011
Taxotere for Breast Cancer
2
Patient Review
3/14/2014
Taxotere for Non-Small Cell Lung Cancer
1
Patient Review
7/22/2010
Taxotere for Cancer Involving the Head or Neck
1
Patient Review
6/18/2014
Taxotere for Breast Cancer
Patient Q&A Section about taxotere
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What are the side effects of Taxotere?
"-Side effects such as pain or swelling at the injection site, nausea, vomiting, diarrhea, excessive tearing, fatigue, dizziness, drowsiness, feeling drunk, constipation, and loss of appetite may occur.
-Temporary hair loss and nail changes may also occur.
-This medication can decrease your body's ability to fight an infection."
Answered by AI
What is the most common side effect of docetaxel?
"Two common long-term side effects of docetaxel chemotherapy are sensory and motor peripheral neuropathy, which are less severe than with paclitaxel. Grade 3 and 4 neuropathy is only observed in less than 10% of patients receiving docetaxel therapy."
Answered by AI
How long can you take Taxotere?
"Health care providers give Taxotere to their patients through an IV. The IV takes one hour to administer the drug, and this happens every three weeks. Depending on the type of cancer, the patient may have to go through several cycles of this treatment."
Answered by AI
Is Taxotere a strong chemo drug?
"Because Taxotere is a strong chemotherapy drug, its side effects tend to be more extreme than drugs that treat other, less serious issues. To deal with these side effects, doctors may lower the dose or prescribe drugs that reduce the risk of allergic reactions."
Answered by AI